PBU The Pension Fund of Early Childhood & Youth Educators purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE – Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 527,871 shares of the company’s stock, valued at approximately $9,106,000.
Several other institutional investors and hedge funds also recently bought and sold shares of KVUE. Norges Bank bought a new position in Kenvue in the 4th quarter worth approximately $756,862,000. Van ECK Associates Corp boosted its holdings in shares of Kenvue by 101.3% in the third quarter. Van ECK Associates Corp now owns 18,361,581 shares of the company’s stock worth $298,008,000 after acquiring an additional 9,240,434 shares during the period. American Century Companies Inc. boosted its holdings in shares of Kenvue by 22.4% in the third quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock worth $601,267,000 after acquiring an additional 6,781,640 shares during the period. Bessemer Group Inc. boosted its holdings in shares of Kenvue by 156.2% in the fourth quarter. Bessemer Group Inc. now owns 8,491,343 shares of the company’s stock worth $146,475,000 after acquiring an additional 5,177,404 shares during the period. Finally, Mondrian Investment Partners LTD bought a new position in shares of Kenvue in the third quarter worth $79,269,000. 97.64% of the stock is owned by institutional investors.
Kenvue Stock Performance
NYSE KVUE opened at $17.72 on Friday. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $22.87. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. The stock has a market capitalization of $34.01 billion, a PE ratio of 20.84, a P/E/G ratio of 1.34 and a beta of 0.54. The company’s 50 day simple moving average is $17.37 and its two-hundred day simple moving average is $17.48.
Kenvue Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were paid a $0.2075 dividend. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 annualized dividend and a yield of 4.7%. Kenvue’s dividend payout ratio is currently 97.65%.
Wall Street Analyst Weigh In
A number of research firms have recently commented on KVUE. Weiss Ratings lowered Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 29th. Barclays cut their price target on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, April 14th. Citigroup cut their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, April 15th. Canaccord Genuity Group raised their price target on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a report on Wednesday, February 18th. Finally, UBS Group cut their price target on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a report on Tuesday, April 7th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $19.33.
Read Our Latest Report on Kenvue
Insider Transactions at Kenvue
In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.59% of the stock is owned by corporate insiders.
About Kenvue
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
Featured Articles
- Five stocks we like better than Kenvue
- Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
